They point out that the available evidence does not indicate that the dose is the cause
The British Medicines Regulatory Agency (MHRA) said on Monday that the existing evidence did not point out that the AstraZeneca vaccine would cause blood clotting in its recipients, and the pharmaceutical company also defended it in a statement.
The safety official said: “We are carefully reviewing the report, but considering the high doses given and the frequency with which blood clots occur naturally, the existing evidence does not indicate that the vaccine is the cause.” MHRA, Phil Bryan (Phil Bryan).
According to EFE reports, regulators responded to Ireland’s decision announced on Sunday, which temporarily suspended the application of AstraZeneca preparations against Covid-19.
Brian added in a statement: “People should continue to get the Covid-19 vaccine when they are questioned.”
Before the intervention of the British regulator, the pharmaceutical company itself issued a statement last night reiterating the safety of its products and denying that it had a blood clot.
“A careful review of all available data on 17 million people from the European Union and the United Kingdom who were vaccinated with the Covid-19 AstraZeneca vaccine did not find any evidence of increased risk of pulmonary embolism, deep vein thrombosis (DVT), or any age Segment, gender, batch or specific country/region thrombocytopenia,” he said.
According to data collected by the company, as of March 8, there were 15 DVT cases and 22 pulmonary embolisms among vaccinators in the European Union and the United Kingdom.
AstraZeneca emphasized that the ratio is “significantly lower than what is naturally expected in the general population of this size and similar to other licensed Covid vaccines.”
In addition, he insisted that although the number of blood clots in people who participated in clinical trials was very small, it was even lower among people who received the vaccine instead of a placebo.
The Anglo-Swedish company said it also had no evidence of increased bleeding among the 60,000 participants in the trial.
“Regarding quality, there are no confirmed issues related to any batches of vaccines that we use in Europe or other parts of the world. They have been and are being tested by our side and have been independently tested by European health authorities, none of which indicate the cause. . Out of concern,” he reiterated.
AstraZeneca recalled that the European Medicines Agency (EMA) will publish its monthly safety report on its website next week.
Denmark, Norway, Iceland, Bulgaria, Ireland and the Netherlands have suspended the use of the vaccine, while several countries including Austria, Estonia, Latvia, Lithuania and Luxembourg withdrew certain batches when testing for thrombosis cases.
EMA considered that “the benefits of the vaccine continue to outweigh its risks,” and recommended that the use of the preparation continue last week.